14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: A prospective study in 112 patients

A. W. Lemstra*, M. T. Van Meegen, J. P. Vreyling, P. H.S. Meijerink, G. H. Jansen, S. Bulk, F. Baas, W. A. Van Gool

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective: To study the sensitivity and specificity of 14-3-3 testing in a prospective series of patients suspected of having Creutzfeldt-Jakob disease (CJD). Background: The 14-3-3 protein immunoassay on CSF has favorable test characteristics as a premortem diagnostic tool in CJD. However, the 14-3-3 protein is a normal cellular protein expressed in various tissues, and its presence in CSF reflects extensive destruction of brain tissue as in CJD, but also in ischemic stroke and meningoencephalitis. Methods: 14-3-3 was tested in the CSF of a prospective series of 110 consecutive patients suspected of having CJD. Results: The sensitivity was 97% and the specificity was 87% in this series. False-positive results were mainly caused by stroke and meningoencephalitis. Conclusion: The 14-3-3 protein is a highly sensitive and specific marker for CJD when used in the appropriate clinical context.

Original languageEnglish
Pages (from-to)514-516
Number of pages3
JournalNeurology
Volume55
Issue number4
DOIs
Publication statusPublished - 1 Jan 2000
Externally publishedYes

Cite this

Lemstra, A. W., Van Meegen, M. T., Vreyling, J. P., Meijerink, P. H. S., Jansen, G. H., Bulk, S., ... Van Gool, W. A. (2000). 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: A prospective study in 112 patients. Neurology, 55(4), 514-516. https://doi.org/10.1212/WNL.55.4.514